☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
Von Hippel-Lindau Disease
Merck Reports the US FDA's Acceptance of NDA for Priority Review of Belzutifan (MK-6482) to Treat Patients with Von Hippel-Lindau...
March 16, 2021
Load more...
Back to Home